AU717611B2 - Tumor-specific antibody fragments, fusion proteins, and uses thereof - Google Patents

Tumor-specific antibody fragments, fusion proteins, and uses thereof Download PDF

Info

Publication number
AU717611B2
AU717611B2 AU41355/96A AU4135596A AU717611B2 AU 717611 B2 AU717611 B2 AU 717611B2 AU 41355/96 A AU41355/96 A AU 41355/96A AU 4135596 A AU4135596 A AU 4135596A AU 717611 B2 AU717611 B2 AU 717611B2
Authority
AU
Australia
Prior art keywords
antibody
molecule
region
chain
encodes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU41355/96A
Other languages
English (en)
Other versions
AU4135596A (en
Inventor
Itai Benhar
Ulrich Brinkmann
David Fitzgerald
Sun-Hee Jung
Byungkook Lee
Eduardo A Padlan
Lee Pai
Ira Pastan
Mark Willingham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
US Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/331,397 external-priority patent/US5981726A/en
Priority claimed from US08/331,396 external-priority patent/US5889157A/en
Priority claimed from US08/331,398 external-priority patent/US5608039A/en
Application filed by US Department of Health and Human Services, US Government filed Critical US Department of Health and Human Services
Publication of AU4135596A publication Critical patent/AU4135596A/en
Application granted granted Critical
Publication of AU717611B2 publication Critical patent/AU717611B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU41355/96A 1994-10-28 1995-10-26 Tumor-specific antibody fragments, fusion proteins, and uses thereof Ceased AU717611B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US08/331397 1994-10-28
US08/331396 1994-10-28
US08/331,397 US5981726A (en) 1990-10-12 1994-10-28 Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof
US08/331,396 US5889157A (en) 1990-10-12 1994-10-28 Humanized B3 antibody fragments, fusion proteins, and uses thereof
US08/331,398 US5608039A (en) 1990-10-12 1994-10-28 Single chain B3 antibody fusion proteins and their uses
US08/331398 1994-10-28
PCT/US1995/013811 WO1996013594A1 (fr) 1994-10-28 1995-10-26 Fragments d'anticorps a specificite tumorale, proteines de fusion, et leurs utilisations

Publications (2)

Publication Number Publication Date
AU4135596A AU4135596A (en) 1996-05-23
AU717611B2 true AU717611B2 (en) 2000-03-30

Family

ID=27406791

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41355/96A Ceased AU717611B2 (en) 1994-10-28 1995-10-26 Tumor-specific antibody fragments, fusion proteins, and uses thereof

Country Status (4)

Country Link
EP (1) EP0796334A1 (fr)
AU (1) AU717611B2 (fr)
CA (1) CA2203236A1 (fr)
WO (1) WO1996013594A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026394A1 (fr) * 1998-10-31 2000-05-11 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Variants de l'anticorps monoclonal anti-carcinome de type humain cc49
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US20050037420A1 (en) * 2001-09-14 2005-02-17 Mei-Yun Zhang Immunoglobulin having particular framework scaffold and methods of making and using
CA2420494A1 (fr) * 2003-02-28 2004-08-28 Universite De Sherbrooke Fonction de l'antigene tumoral ca 125 et utilisations therapeutiques de celui-ci
CA2490659C (fr) 2002-06-28 2014-08-19 Syed V. S. Kashmiri Les cc49, anti-tag-72 humanises servant au diagnostic et au traitement de tumeurs chez l'homme
CU23403A1 (es) 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
US7589181B2 (en) 2003-08-29 2009-09-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
GB201910899D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Binding members

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3512795B2 (ja) * 1991-09-30 2004-03-31 アメリカ合衆国 組換免疫毒素

Also Published As

Publication number Publication date
AU4135596A (en) 1996-05-23
WO1996013594A8 (fr) 2000-04-06
WO1996013594A1 (fr) 1996-05-09
CA2203236A1 (fr) 1996-05-09
EP0796334A1 (fr) 1997-09-24

Similar Documents

Publication Publication Date Title
US5608039A (en) Single chain B3 antibody fusion proteins and their uses
US6287562B1 (en) Methods of inhibiting the growth of cells bearing LewisY antigens using B1, B3, or B5 targeted immunoconjugates
JP6728264B2 (ja) 抗her2抗体及びその結合体
AU770718B2 (en) Use of genetically engineered antibodies to CD38 to treat multiple myeloma
CA2187283C (fr) Ligands et molecules chimeriques a permutation circulaire
Reiter et al. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.
EP0703926B1 (fr) Fragments de polypeptide recombine stabilises par disulfure possedant une specificite de liaison
US5981726A (en) Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof
EP0699756B1 (fr) Anticorps BR96 mutantsréagissant aux carcinomes humains
US20040091485A1 (en) Humanised antibodies to the epidermal growth factor receptor
JP2008208131A (ja) Cd22を保有する細胞および腫瘍へ標的化された、組換え抗体および免疫複合体
AU2001249760A1 (en) Mucin-1 specific binding members and methods of use thereof
WO2001075110A2 (fr) Elements de liaison specifiques de la mucine-1 et techniques d'utilisation
US20060193771A1 (en) Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins
AU717611B2 (en) Tumor-specific antibody fragments, fusion proteins, and uses thereof
CN113631582A (zh) 一种融合蛋白及其用途
JPH07502643A (ja) 組換免疫毒素
AU2003298794A2 (en) Recombinant immunotoxin and use in treating tumors
US5728821A (en) Mutant BR96 antibodies reactive with human carcinomas
RU2814164C2 (ru) Антитело против клаудина 18.2 и его конъюгат антитело-лекарственное средство
JPH10508202A (ja) 腫瘍特異性抗体断片、融合タンパク質、およびそれらの使用
KR20230135653A (ko) 항-클라우딘 18.2 항체 및 이의 항체-약물 접합체
Willingham et al. Assignee
BR112016002752B1 (pt) Anticorpo ou seus fragmentos funcionais que pode especificamente se ligar ao her2, conjugados, composição farmacêutica, e, uso do anticorpo ou seus fragmentos funcionais, do conjugado ou da composição farmacêutica

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 13, NO 44, PAGE(S) 6728 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO PATENT APPLICATION NO. 41355/96

FGA Letters patent sealed or granted (standard patent)